2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $117M | $205M | $276M | $310M | $309M |
Cost of Revenue | $5M | $4.4M | $11M | $25M | $28M |
Gross Profit | $112M | $200M | $266M | $285M | $280M |
Gross Profit % | 96% | 98% | 96% | 92% | 91% |
R&D Expenses | $0.56 | $0.56 | $0.56 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $66M | $114M | $154M | $166M | $162M |
Dep. & Amort. | $28M | $42M | $61M | $67M | $71M |
Def. Tax | -$2.8M | -$340K | $0 | $0 | $0 |
Stock Comp. | $3.3M | $8.6M | $18M | $20M | $17M |
Chg. in WC | $14M | $18M | -$216M | $4.9M | $3.9M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $126M | $81M | $87M | $140M | $146M |
ST Investments | $619M | $325M | $201M | $0 | $0 |
Cash & ST Inv. | $126M | $81M | $87M | $140M | $146M |
Receivables | $0 | $13M | $17M | $22M | $23M |
Inventory | $0 | $417M | $0 | $0 | $0 |
Generated $308.5M in total revenues and $256.1M in AFFO for 2024, with a strong balance sheet featuring 11% debt to total gross assets and over $235M in liquidity.
Deployed $70M in capital for acquisitions and improvements, executed leases totaling 530,000 square feet, and achieved 98% portfolio occupancy by year-end.
Resolved tenant issues with PharmaCann, including recommencing rent payments on nine leases and securing a junior secured note, while maintaining a firm stance on lease agreements with other tenants.
Highlighted growth prospects in the cannabis industry, with projected 10% sales growth in 2025 and significant state-level developments in Pennsylvania, Florida, New York, and Ohio.
Continued focus on disciplined investments in cultivation properties and multistate operators, while monitoring tenant health and navigating industry headwinds such as illicit market competition and regulatory uncertainty.